pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 31 Non-oncology: 23
Oncology: 8
Under Consideration for Negotiation 19 Non-oncology: 5
Oncology: 14
Completed Negotiations 876 With Letter of Intent: 759
Without agreement: 117
Negotiations That Were Not Pursued 112

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Tremfya Janssen Inc. Crohn's disease
Tremfya Janssen Inc. Ulcerative Colitis
Opdivo-Yervoy Bristol Myers Squibb Canada Inc. For the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Pombiliti with Opfolda Amicus Therapeutics Canada Inc. Pompe disease
Piasky Hoffmann-La Roche Ltd. Paroxysmal nocturnal hemoglobinuria (PNH)

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Jemperli GlaxoSmithKline Inc. ​In combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
Nubeqa Bayer Inc. For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Stivarga Bayer Inc. For the treatment of metastatic osteosarcoma in patients who received at least 1 prior line of therapy.
Polivy Hoffmann-La Roche Ltd. In combination with R-CHP for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (E
Bylvay Medison Pharma Canada Inc. Alagille syndrome
Skyrizi AbbVie Corporation Ulcerative Colitis
Repatha Amgen Canada Inc. Atherosclerotic cardiovascular disease
Winrevair Merck Canada Inc. Pulmonary Arterial Hypertension (WHO group 1)
Tagrisso AstraZeneca Canada Inc. ​For the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in co
Olumiant Eli Lilly Canada Inc. Alopecia areata, severe

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Wegovy Novo Nordisk Canada Inc. As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at leas
Pavblu Amgen Canada Inc. Multiple Indications
Methofill Accord Healthcare Inc. Multiple Indications

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks